Partner in relationship

Hatteras Raises $200M for Two New Funds Following HistoSonics Exit Success

1 week ago talkbio0Tagged Biological Science Disciplines, Early-stage, Hatteras, Hatteras Opportunity Fund I, Hatteras Venture Fund VII, HistoSonics exit, medtech, Partner in relationship, startups, venture capital

Hatteras Venture Partners; $200M; venture capital; life sciences; early-stage startups; biotech; medtech; HistoSonics exit; fundraising; Hatteras Venture Fund VII; Hatteras Opportunity Fund I

Dispatch Bio Launches with $216M and CAR-T Pioneer Carl June to Advance Universal Solid Tumor Immunotherapy

1 month ago talkbio0Tagged Arch of foot, Cancer Therapeutic Procedure, CAR-T, Carl June, Dispatch Bio, Flare platform, Funding, Immunotherapy, Parker Institute for Cancer Immunotherapy, Partner in relationship, Series, Solid Neoplasm, venture

Dispatch Bio; solid tumors; immunotherapy; CAR-T; Carl June; Series A funding; Flare platform; Parker Institute for Cancer Immunotherapy; ARCH Venture Partners; universal cancer treatment

BioAtla lays off 30% of staff, hunts out partners for ADC and cancer antibody

5 months ago talkbio0Tagged 30%, BioAtla, CAB, Partner in relationship, Staff

Staff, Partner in relationship, CAB, BioAtla, 30%

Sofinnova Partners Launches Three New Biotechs with €165M Acceleration Fund

5 months ago talkbio0Tagged Acceleration, BioClec, Funds, Partner in relationship, pharmaceutical backing, Sofinnova, venture

Sofinnova Partners, biotech acceleration fund, BioClec, Forth Therapeutics, Signadori Bio, venture capital, pharmaceutical backing

Ouro Medicines Launches with $120M Funding to Develop Immune Reset Therapeutics for Chronic Immune-Mediated Diseases

7 months ago talkbio0Tagged Capital, Chronic Immune-Mediated Diseases, engagers, immune reset, innovations, Monograph, NEA, Norwest, Ouro Medicines, Partner in relationship, SmithKline Beecham, T-Lymphocyte, TPG, venture

Ouro Medicines, Immune Reset Therapeutics, Chronic Immune-Mediated Diseases, T Cell Engagers, B Cell Mediated Diseases, GSK, Monograph Capital, TPG Life Sciences Innovations, NEA, Norwest Venture Partners